Loading
AMEXHealthcareBiotechnology
Latest quote
$1.56
−$0.06 · -3.70%
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Latest quote
$1.56
−$0.06 · -3.70%
Regular session · ET · Market data may be delayed.
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Day range
Current $1.56
52-week range
Current $1.56
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
25
Expensive
Sentiment
56
Mixed
Risk
55
Elevated Risk
Momentum
44
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
Day range
Current $1.56
52-week range
Current $1.56
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 363.09K USD | 2.78K USD | 4.22K USD | 805 USD | 1.16M USD |
| Gross profit | −363.09K USD | −2.78K USD | −4.22K USD | −805 USD | −1.16M USD |
| Research and development | 16.36B USD | 2.84M USD | 3.22M USD | 3.29M USD | 2.17M USD |
| Selling, general, and administrative | 12.34B USD | 3.97M USD | 1.12M USD | 1.15M USD | 1.5M USD |
| Operating expenses | 28.34M USD | 6.81M USD | 4.34M USD | 4.45M USD | 3.68M USD |
| Interest income | 249 USD | — | — | — | — |
| Interest expense | — | 2.05M USD | 3.45M USD | 1.81M USD | 2.58M USD |
| Depreciation and amortization | 363.09K USD | 2.78K USD | 4.22K USD | 805 USD | 805 USD |
| Operating income | −28.71M USD | −6.81M USD | −4.34M USD | −4.45M USD | −4.84M USD |
| Net income | −28.75M USD | −8.88M USD | −7.79M USD | −6.25M USD | −7.42M USD |
Company facts updated Oct 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Limited analyst sample: 4 ratings. Interpret the distribution with caution.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI703.23K0.00%2.3T USD0.03%$381.22-0.19%
Vanguard Extended Market ETFVXF611K0.00%95.4B USD0.05%$233.45-0.66%
iShares Micro-Cap ETFIWC181.96K0.01%1.32B USD0.60%$181.87-0.62%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM70K0.06%116.88M USD0.73%$15.86-0.50%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
